Treatment of squamous cell anal cancer with IMRT and simultaneous hypofractionated boost combined with concurrent chemotherapy

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter L. Diaz Gomez
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors L. Diaz Gomez1, P. Ramirez Daffos1, A. Seguro Fernandez2, J. Jaen Olasolo1
  • 1HU Puerta del Mar, Cadiz, Spain, /
  • 2HU Rey Juan Carlos, Mostoles, Spain, /


Squamous cell anal canal carcinoma is a rather rare malignancy, no more than 4% of all gastrointestinal tumors although is incident is increasing. Definitive chemoradiation is the standard management for anal squamous cell carcinoma. The aim of this study is to evaluate the outcome and toxicity of our institutional new schedule with intensity modulated radiation therapy and simultaneous boost plus concurrent chemotherapy for these patients.